HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Zoster immunoglobulin in varicella prophylaxis. A study among high-risk patients.

Abstract
The efficacy of zoster immunoglobulin (ZIG) in preventing varicella was studied among patients in a high-risk group. 173 non-immune patients were observed after exposure to varicella-zoster (VZ) virus and subsequent administration of ZIG. For 138 patients (80%) no sign of varicella was recorded, 16 patients (9%) had a subclinical infection and 19 patients (11%) developed varicella. 12/19 patients with varicella contracted a very mild disease (less than 20 pocks, negligible fever), 5 got mild or normal disease and 2 children, both with acute lymphatic leukemia, developed more pronounced symptoms. Three patients protected by 0.15 ml ZIG/kg body weight after heavy exposure to VZ virus, were not protected at a second exposure 2 weeks later. In an enlarged study group of high-risk patients where 52 patients receiving ZIG developed varicella, the mean incubation period for 42 patients was 21 days. Leukemic patients were found to have a higher frequency of clinical varicella, more pronounced symptoms and a slightly longer incubation period than other high-risk patients. VZ specific antibody titers were compared for various immunoglobulin preparations and found to be 30 times higher in zoster immunoglobulins than in normal immunoglobulins.
AuthorsK Hanngren, L Falksveden, M Grandien, G Lidin-Janson
JournalScandinavian journal of infectious diseases (Scand J Infect Dis) Vol. 15 Issue 4 Pg. 327-34 ( 1983) ISSN: 0036-5548 [Print] England
PMID6318302 (Publication Type: Journal Article)
Chemical References
  • Antibodies, Viral
Topics
  • Antibodies, Viral (immunology)
  • Chickenpox (immunology, prevention & control)
  • Child
  • Child, Preschool
  • Female
  • Herpes Zoster (immunology)
  • Herpesvirus 3, Human (immunology)
  • Humans
  • Immunization, Passive
  • Male

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: